Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The study was prematurely terminated on 26Jul2011 due to the undesirable PK characteristics of PF-03758309 and the lack of an observed dose-response relationship. There were no safety concerns that contributed to the study termination.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
ECOG (Eastern Cooperative Oncology Group) Performance Status (PS) must be 0 or 1.
Adequate bone marrow, liver and kidney function.
You may not be if
Patients with known brain metastases.
Previous high dose chemotherapy requiring stem cell rescue.
Prior irradiation to \>25% of the bone marrow.
Active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
Current active treatment in another clinical study.
Pregnancy or breast feeding.
Active inflammatory gastrointestinal disease, chronic diarrhea (unless related to underlying malignancy or prior related treatment) or history of abdominal fistula, gastrointestinal perforation, peptic ulcer disease, or intra-abdominal abscess within 6 months prior to study enrollment.
